ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

MDST Medicsight

0.45
0.00 (0.00%)
10 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Medicsight LSE:MDST London Ordinary Share GB00B1YD4B09 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.45 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

MGT Announces Strategic Review and Board Changes

10/02/2011 7:47pm

PR Newswire (US)


Medicsight (LSE:MDST)
Historical Stock Chart


From Jan 2020 to Jan 2025

Click Here for more Medicsight Charts.

NEW YORK, Feb. 10, 2011 /PRNewswire/ -- MGT Capital Investments, Inc. (AMEX: MGT), ("MGT"), announced today that Allan Rowley has resigned as Chief Executive Officer and as a Director of MGT.  Richard Cohen, Esq. has joined the Company as an independent Director to replace Mr. Rowley.  In addition, Robert Ladd, presently a Director of the Company, has been appointed by the Board to the position of Interim CEO pending an executive search.  

"We are pleased that Richard has agreed to join the Board of MGT," stated Peter Venton, Chairman of the Board of MGT.  "Richard is not only a highly respected lawyer and President of the law firm Lowey Dannenberg, but also has excellent judgment and is an expert in the area of corporate governance."

Mr. Venton continued, "We would also like to take this opportunity to thank Allan for his contributions to the Company over the past five years."  Robert Ladd added, "I am happy to step in as Allan devotes his full-time efforts to MGT's majority-owned subsidiary Medicsight PLC (London AIM: MDST).  MDST is anticipating an exciting period in the development and marketing of its computer-aided detection platform for use in the CT Colonography market post regulatory approval in the US and Japan."

As an additional action, the Board of MGT has decided to explore all alternatives with respect to maximizing the value of its holdings of Medicsight PLC, including, but not limited to, the previous decision of a pro-rata dividend to MGT stockholders.  "It is the view of the Board of MGT, that the current public trading price of Medicsight does not reflect the potential value of the intellectual property portfolio and balance sheet," concluded Peter Venton.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.

For further information:

MGT Capital Investments

Robert Ladd

Tel: 212-652-3214

rladd@mgtci.com

www.mgtci.com  





SOURCE MGT Capital Investments, Inc.

Copyright 2011 PR Newswire

1 Year Medicsight Chart

1 Year Medicsight Chart

1 Month Medicsight Chart

1 Month Medicsight Chart